Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

Medical glue vs. internal bleeding: a new hope?

NCT ID NCT07753005

Disease control Sponsor: Aesculap AG Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting This study
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 07, 2026 · Last updated Aug 07, 2026

Summary

This study is looking at how well a medical glue called Histoacryl stops bleeding from arteries in the chest or abdomen. It will follow adults in Japan who receive this treatment during routine care to see if it works and is safe. The main goal is to check if bleeding stops within a month without needing another procedure.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Histoacryl (a medical glue used to block bleeding arteries)
What this could lead to
If successful, this could confirm Histoacryl as a reliable option to stop internal bleeding without surgery, potentially improving outcomes for patients with severe hemorrhage.
What could go wrong
This is an observational study, so it doesn't test against a comparison group. Results may vary in real-world settings, and there are risks like incomplete blockage or need for repeat procedures.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 176 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jun 2028

An estimate. End dates often move.

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

Adults with active thoracoabdominal arterial bleeding requiring endovascular embolization will be enrolled at approximately 11 centers in Japan. Eligible patients must be scheduled to undergo embolization with Histoacryl® according to routine clinical practice and within the approved indication in Japan. The study population is expected to include patients with bleeding of various etiologies, including traumatic, iatrogenic, gastrointestinal, pulmonary (hemoptysis), obstetric, neoplastic, or other thoracoabdominal arterial hemorrhages.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Active thoracoabdominal arterial bleeding diagnosed by endoscopy, catheter angiography, or computed tomography angiography (CTA). * Planned embolization treatment using Histoacryl® as the sole embolic agent for the target lesion. * No endoleak following thoracic endovascular aortic repair (TEVAR) or endovascular abdominal aortic repair (EVAR). * Patients with malignant tumors must have an expected survival of at least 1 month. * Written informed consent obtained from the patient or a legally authorized representative. Exclusion Criteria: * Previous embolization in the target vascular territory. * Known allergy or hypersensitivity to n-butyl cyanoacrylate (NBCA), Lipiodol®, or related treatment components. * Use of adjunctive embolic agents in the same target location. * Planned surgical treatment after embolization as part of a predefined two-step treatment strategy. * Severe septicemia. * Participation in another clinical trial. * Target vessels unsuitable for safe Histoacryl® injection. * Empiric embolization without identification of a target bleeding location. * Pregnancy, with the exception of patients treated for postpartum hemorrhage.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Gastrointestinal hemorrhage are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Gastrointestinal Hemorrhage Hemoptysis Hemorrhage Postpartum Hemorrhage

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Gastrointestinal hemorrhage Hemoptysis Hemorrhage Postpartum hemorrhage

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The study's own enquiry address

    This study publishes an address for enquiries. See it below .

  2. The places running it

    11 sites. The list below names each one and where it is.

  3. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  4. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Study contacts

  • Contact

    Email: •••••@•••••

Locations

  • Aichi Cancer Center Hospital

    Nagoya, Aichi-ken, 464-8681, Japan

  • Fujita Health University Hospital

    Toyoake, Aichi-ken, 470-1192, Japan

  • Gifu University Hospital

    Gifu, Gifu, 501-1194, Japan

  • Hokkaido University Hospital

    Sapporo, Hokkaido, 060-8648, Japan

  • Hyogo Medical University Hospital

    Nishinomiya, Hyōgo, 663-8501, Japan

  • Nara Medical University Hospital

    Kashihara, Nara, 634-8522, Japan

  • National Cancer Center Hospital East

    Kashiwa, Chiba, 277-8577, Japan

  • National Cancer Center Hospital,

    Tokyo, Tokyo, 104-0045, Japan

  • Shizuoka Cancer Center

    Nagaizumi-chō, Shizuoka, 411-8777, Japan

  • St. Marianna University Hospital

    Kawasaki, Kawasaki, 216-8511, Japan

  • Teikyo University Hospital

    Tokyo, Tokyo, 173-8606, Japan

More trials for these conditions

Other studies related to the condition(s) this trial covers.